NANO.PA
Price:
$3.224
Market Cap:
$151.89M
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.[Read more]
Industry
Biotechnology
IPO Date
2012-10-29
Stock Exchange
EURONEXT
Ticker
NANO.PA
According to Nanobiotix S.A.’s latest financial reports and current stock price. The company's current ROE is 283.43%. This represents a change of 26.59% compared to the average of 223.90% of the last 4 quarters.
The mean historical ROE of Nanobiotix S.A. over the last ten years is 409.95%. The current 283.43% ROE has changed -30.86% with respect to the historical average. Over the past ten years (40 quarters), NANO.PA's ROE was at its highest in in the December 2019 quarter at 1.32%. The ROE was at its lowest in in the June 2022 quarter at -1522.65%.
Average
409.95%
Median
-53.63%
Minimum
-213.05%
Maximum
2.50%
Discovering the peaks and valleys of Nanobiotix S.A. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 921.33%
Maximum Annual ROE = 2.50%
Minimum Annual Increase = -1272.04%
Minimum Annual ROE = -213.05%
Year | ROE | Change |
---|---|---|
2023 | 2.15% | 921.33% |
2022 | 210.91% | -219.77% |
2021 | -176.09% | 268.87% |
2020 | -47.74% | -101.91% |
2019 | 2.50% | -1272.04% |
2018 | -213.05% | 257.94% |
2017 | -59.52% | -52.67% |
2016 | -125.76% | 15.47% |
2015 | -108.92% | 245.50% |
2014 | -31.52% | -87.69% |
The current ROE of Nanobiotix S.A. (NANO.PA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
729.64%
5-year avg
927.65%
10-year avg
409.95%
Nanobiotix S.A.’s ROE is greater than Genfit S.A. (1.77%), greater than Innate Pharma S.A. (-84.39%), greater than ERYTECH Pharma S.A. (-84.88%), greater than Cellectis S.A. (-75.49%), less than Adocia SA (360.25%),
Company | ROE | Market cap |
---|---|---|
1.77% | $175.76M | |
-84.39% | $157.29M | |
-84.88% | $48.66M | |
-75.49% | $124.86M | |
360.25% | $110.39M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Nanobiotix S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Nanobiotix S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Nanobiotix S.A.'s ROE?
How is the ROE calculated for Nanobiotix S.A. (NANO.PA)?
What is the highest ROE for Nanobiotix S.A. (NANO.PA)?
What is the 3-year average ROE for Nanobiotix S.A. (NANO.PA)?
What is the 5-year average ROE for Nanobiotix S.A. (NANO.PA)?
How does the current ROE for Nanobiotix S.A. (NANO.PA) compare to its historical average?